Therapeutic Targeting of Epigenetic Components in Amyotrophic Lateral Sclerosis (ALS)

ISSN: 1875-533X (Online)
ISSN: 0929-8673 (Print)

Volume 22, 38 Issues, 2015

Download PDF Flyer

Current Medicinal Chemistry

Aims & ScopeAbstracted/Indexed in

Ranking and Category:
  • 6th of 59 in Chemistry & Medicinal
  • 47th of 254 in Pharmacology & Pharmacy
  • 81st of 289 in Biochemistry & Molecular Biology

Submit Abstracts Online Submit Manuscripts Online

Atta-ur-Rahman, FRS
Honorary Life Fellow
Kings College
University of Cambridge

View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Current: 3.853
5 - Year: 4.115

Select Language (选择语言):

Therapeutic Targeting of Epigenetic Components in Amyotrophic Lateral Sclerosis (ALS)

Current Medicinal Chemistry, 21(31): 3576-3582.

Author(s): J. Lee, H. Ryu, G. Keum, Y.J. Yoon, N.W. Kowall and H. Ryu

Affiliation: VA Boston Healthcare System and Department of Neurology, Boston University School of Medicine, 150 South Huntington Avenue, Boston, MA 02130; USA.


Amyotrophic lateral sclerosis (ALS) is an adult-onset motor neuron disease characterized by degeneration of motor neuron and glial activation followed by the progressive muscle loss and paralysis. Numerous distinct therapeutic interventions have been examined but currently ALS does not have a cure or an efficacious treatment for the disorder. Glutamate- induced excitotoxicity, inflammation, mitochondrial dysfunction, oxidative stress, protein aggregation, transcription deregulation, and epigenetic modifications are associated with the pathogenesis of ALS and known to be therapeutic targets in ALS. In this review, we discuss translational pharmacological studies targeting epigenetic components to ameliorate ALS. Understanding of the epigenetic mechanisms will provide novel insights that will further identify potential biological markers and therapeutic approaches for treating ALS. A combination of treatments that modulate epigenetic components and multiple targets may prove to be the most effective therapy for ALS.


Amyotrophic lateral sclerosis, epigenetic components, HDAC inhibitor, motor neuron, transcription, therapeutics.

Purchase Online Order Reprints Order Eprints Rights and Permissions


Article Details

Volume: 21
Issue Number: 31
First Page: 3576
Last Page: 3582
Page Count: 7
DOI: 10.2174/0929867321666140706131825

Related Journals

Webmaster Contact: Copyright © 2015 Bentham Science